Cetera Investment Advisers Seagen Inc. Transaction History

Cetera Investment Advisers

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $117,970 - $133,154	616 Added 15.16%	4,680 $992,000
Q2 2023 Aug 09, 2023	SELL	$187.64 - $206.25 $86,689 - $95,287	-462 Reduced 10.21%	4,064 $782,000
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $6,634 - $10,560	52 Added 1.16%	4,526 $916,000
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $70,069 - $83,084	597 Added 15.4%	4,474 $574,000
Q3 2022 Nov 10, 2022	BUY	$135.27 - $180.11 $10,280 - $13,688	76 Added 2.0%	3,877 $530,000
Q2 2022 Aug 11, 2022	SELL	$108.81 - $179.33 $20,347 - $33,534	-187 Reduced 4.69%	3,801 $673,000
Q1 2022 May 13, 2022	SELL	$119.61 - $157.85 $54,900 - $72,453	-459 Reduced 10.32%	3,988 $574,000
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $106,072 - $141,999	744 Added 20.09%	4,447 $688,000
Q3 2021 Nov 16, 2021	SELL	$142.45 - $169.82 $21,225 - $25,303	-149 Reduced 3.87%	3,703 $629,000
Q2 2021 Aug 13, 2021	BUY	$135.08 - $161.1 $81,048 - $96,660	600 Added 18.45%	3,852 $608,000
Q1 2021 May 17, 2021	SELL	$137.51 - $190.8 $105,470 - $146,343	-767 Reduced 19.08%	3,252 $452,000
Q4 2020 Feb 17, 2021	BUY	$164.63 - $211.93 $661,647 - $851,746	4,019 New	4,019 $704,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

Stay updated on Cetera Investment Advisers with notifications on news.